Comparative Pharmacology
Head-to-head clinical analysis: ATENOLOL AND CHLORTHALIDONE versus ORETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATENOLOL AND CHLORTHALIDONE versus ORETIC.
ATENOLOL AND CHLORTHALIDONE vs ORETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atenolol is a cardioselective beta-1 adrenergic receptor antagonist that reduces heart rate, myocardial contractility, and blood pressure. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and peripheral resistance.
Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased excretion of water and electrolytes.
1 tablet (atenolol 50 mg/chlorthalidone 25 mg) orally once daily. May be increased to 2 tablets once daily.
25-100 mg orally once or twice daily; maximum 200 mg/day.
None Documented
None Documented
Atenolol: 6-7 hours (prolonged to 14-27 hours in severe renal impairment); Chlorthalidone: 40-60 hours (allows once-daily dosing).
Terminal elimination half-life: 6-15 hours (average 10 hours); prolonged in renal impairment and heart failure; clinical context: duration of diuretic effect correlates with half-life, requiring once or twice daily dosing.
Atenolol: ~50% eliminated unchanged in urine; Chlorthalidone: ~50-70% eliminated unchanged in urine, remainder as metabolites via renal and biliary routes (<10% fecal).
Renal: approximately 95% (primarily as unchanged drug via tubular secretion), Biliary/fecal: <5%
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic